Pulmonx Corporation (NASDAQ:LUNG – Get Free Report) General Counsel David Lehman sold 14,334 shares of the firm’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $2.26, for a total value of $32,394.84. Following the completion of the transaction, the general counsel owned 361,827 shares in the company, valued at approximately $817,729.02. This trade represents a 3.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Pulmonx Stock Down 2.2%
Pulmonx stock opened at $2.21 on Friday. Pulmonx Corporation has a one year low of $1.13 and a one year high of $2.89. The stock has a fifty day moving average of $1.82 and a 200 day moving average of $1.57. The company has a debt-to-equity ratio of 0.95, a quick ratio of 3.52 and a current ratio of 4.32. The stock has a market cap of $94.92 million, a PE ratio of -1.91 and a beta of 0.34.
Pulmonx (NASDAQ:LUNG – Get Free Report) last released its quarterly earnings results on Wednesday, July 29th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.04. Pulmonx had a negative return on equity of 96.66% and a negative net margin of 55.03%.The business had revenue of $22.76 million during the quarter, compared to the consensus estimate of $22.39 million. As a group, sell-side analysts predict that Pulmonx Corporation will post -1.05 EPS for the current year.
Pulmonx News Roundup
- Positive Sentiment: Analyst sentiment remains broadly favorable, with three Buy ratings and one Sell rating producing a “Moderate Buy” consensus. The average price target of $7.67 is substantially above recent trading levels, suggesting significant potential upside if Pulmonx delivers on its growth plans. Pulmonx analyst and earnings information
- Positive Sentiment: Pulmonx’s latest quarterly results exceeded expectations: revenue was $22.76 million versus the $22.39 million consensus estimate, while its loss of $0.24 per share was narrower than the expected $0.28 loss. Pulmonx quarterly results
- Neutral Sentiment: CEO Glendon French III, General Counsel David Lehman, Geoffrey Rose and Srikanth Radhakrishnan sold a combined 78,340 shares at approximately $2.26 per share. The filings say the transactions covered tax-withholding obligations related to vested equity awards, reducing their significance as a signal of declining confidence; however, the sales may add modest short-term supply. Pulmonx insider sales report
- Negative Sentiment: Recent gains have triggered profit-taking, contributing to the stock’s retreat and weakening short-term trading sentiment. Pulmonx shares fall following recent gains
- Negative Sentiment: Pulmonx remains unprofitable, and analysts expect a full-year loss of roughly $1.05 per share. The company’s negative margins and uncertain path to sustained profitability are keeping investors cautious despite the earnings beat. Pulmonx profit-taking and earnings outlook
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on the stock. Wall Street Zen raised shares of Pulmonx from a “sell” rating to a “hold” rating in a research report on Saturday, June 27th. Weiss Ratings raised shares of Pulmonx from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 25th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Pulmonx presently has a consensus rating of “Moderate Buy” and an average target price of $7.67.
Check Out Our Latest Stock Analysis on LUNG
Hedge Funds Weigh In On Pulmonx
A number of hedge funds have recently made changes to their positions in LUNG. Cerity Partners LLC bought a new stake in Pulmonx during the 4th quarter valued at approximately $27,000. Opal Capital LLC bought a new stake in shares of Pulmonx during the fourth quarter valued at approximately $29,000. Lazard Asset Management LLC purchased a new position in shares of Pulmonx in the fourth quarter worth $31,000. Jain Global LLC bought a new position in shares of Pulmonx during the third quarter worth $30,000. Finally, R Squared Ltd purchased a new position in Pulmonx during the first quarter valued at $26,000. Institutional investors own 91.04% of the company’s stock.
Pulmonx Company Profile
Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.
The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.
Featured Articles
- Five stocks we like better than Pulmonx
- Zscaler’s Strong Quarter Still Left Investors Waiting on 1 Key Signal
- Is Duolingo the Next Netflix-Style Comeback Story?
- GitLab’s AI Tools Are Starting to Turn Developer Demand Into Real Revenue
- GTA VI’s Console Problem Isn’t Take-Two’s Problem
Receive News & Ratings for Pulmonx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmonx and related companies with MarketBeat.com's FREE daily email newsletter.
